logo-loader
viewCircassia Pharmaceuticals PLC

Circassia brings in top Pfizer exec as new chief operating officer

Jonathan Emms, who will officially join in September, arrives at a time when Circassia is transitioning into a more commercially-focused business

Circassia Pharmaceuticals - Circassia brings in top Pfizer exec as new chief operating officer
Emms oversaw the launch of Serevent and Spiriva – two huge COPD drugs

Circassia Pharmaceuticals PLC (LON:CIR) has hired one of Pfizer’s top executives to become its first chief operating officer.

Jonathan Emms, who has held a number of senior positions at both Pfizer and GlaxoSmithKline PLC (LON:GSK), will join the respiratory drug specialist next month.

Upon his arrival, Circassia’s long-serving senior vice president of R&D, Rod Hafner, will step down from the board, although he will remain a “key member” of the senior management team.

READ: Circassia gets double shot in the arm from US regulators

The boardroom changes come as Circassia transitions into a more commercially-focused company, following the recent regulatory approvals for two of its chronic obstructive pulmonary disease (COPD) treatments – Duaklir and Tudorza.

“With our preparations well advanced for the forthcoming US launch of Duaklir, the ongoing establishment of our new Chinese sales team in the marketplace and our growing commercial presence in Europe, we look forward to Jonathan leading our commercial strategy,” said chief executive Steve Harris.

“At the same time, we thank Rod for his major contribution to the company, managing Circassia's input into the successful Duaklir NDA and Tudorza sNDA and leading our R&D activities over many years.”

Emms added: “I am impressed with the team's ambition and clear drive to build a highly successful specialty pharmaceutical business, and am certain that with my international commercial experience and knowledge of the respiratory market I can make a significant contribution helping Circassia achieve its goal.”

Shares were up 1.8% to 19.5p in early deals on Monday.

Quick facts: Circassia Pharmaceuticals PLC

Price: 17.1 GBX

LSE:CIR
Market: LSE
Market Cap: £64.16 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Pharmaceuticals PLC named herein, including the promotion by the Company of Circassia Pharmaceuticals PLC in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19

2 min read